Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk Newly Diagnosed Multiple Myeloma”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Large-scale testing (Phase 3)Looking for participantsNCT07285239
What this trial is testing

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
PrECOG, LLC. 500
Testing effectiveness (Phase 2)Study completedNCT00075881
What this trial is testing

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)UnknownNCT04935580
What this trial is testing

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05849610
What this trial is testing

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Who this might be right for
High-Risk de Novo Multiple Myeloma
PETHEMA Foundation 30
Testing effectiveness (Phase 2)Ended earlyNCT01239368
What this trial is testing

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Who this might be right for
Myeloma, Plasma-CellMyeloma-MultipleMyelomatosis
National Cancer Institute (NCI) 34
Large-scale testing (Phase 3)Not Yet RecruitingNCT07732712
What this trial is testing

Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells

Who this might be right for
Multiple Myeloma
The Affiliated People's Hospital of Ningbo University 15
Not applicableLooking for participantsNCT07226609
What this trial is testing

A Dietary Study for People With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 220
Testing effectiveness (Phase 2)Study completedNCT01668719
What this trial is testing

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Who this might be right for
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell Myeloma
SWOG Cancer Research Network 142
Testing effectiveness (Phase 2)Looking for participantsNCT06140966
What this trial is testing

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple MyelomaPrimary Plasma Cell LeukemiaExtramedullary Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT06169215
What this trial is testing

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI) 58
Post-approval studies (Phase 4)Not Yet RecruitingNCT07334535
What this trial is testing

Isa-VRD in TIE HRMM

Who this might be right for
Multiple Myeloma
Peking Union Medical College Hospital 117
Testing effectiveness (Phase 2)Study completedNCT01936532
What this trial is testing

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)

Who this might be right for
Newly Diagnosed Multiple Myeloma
Nantes University Hospital 42
Testing effectiveness (Phase 2)Study completedNCT00793572
What this trial is testing

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 32
Large-scale testing (Phase 3)Study completedNCT01916252
What this trial is testing

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 460
Testing effectiveness (Phase 2)Active Not RecruitingNCT03606577
What this trial is testing

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Nantes University Hospital 50
Early research (Phase 1)Looking for participantsNCT06768489
What this trial is testing

JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

Who this might be right for
Multiple MyelomaSmoldering Multiple MyelomaImmunoglobulin Light-chain Amyloidosis
Janssen Research & Development, LLC 276
Testing effectiveness (Phase 2)Looking for participantsNCT07053436
What this trial is testing

Horizon Two: HR NDMM (MMRC-100)

Who this might be right for
High Risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Consortium 300
Testing effectiveness (Phase 2)Ended earlyNCT02897830
What this trial is testing

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma

Who this might be right for
Multiple Myeloma
University Hospital, Toulouse 46
Testing effectiveness (Phase 2)UnknownNCT03188172
What this trial is testing

MUK Nine b: OPTIMUM Treatment Protocol

Who this might be right for
Multiple Myeloma
University of Leeds 95
Early research (Phase 1)WithdrawnNCT04579523
What this trial is testing

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Who this might be right for
Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Fred Hutchinson Cancer Center
Next Page